The GLP-1 Reckoning: How HR Teams Are Redesigning Benefits Under Budget Pressure

Title Tag: GLP-1 Drug Costs Are Reshaping HR Benefits Strategy

Meta Description: GLP-1 drugs are now one of the biggest line items in employer health budgets. Here's how HR teams are redesigning benefits strategy in 2026.

GLP-1 weight-loss drugs like Ozempic and Wegovy have exploded from a niche coverage issue into one of the largest line items in many employers’ pharmacy budgets. A single drug category has blown past most employers’ budget projections, forcing HR and benefits teams to scramble. In 2026, companies are sharply divided between absorbing the cost and pulling back coverage. This article examines how large the cost pressures really are, which employers are doubling down and which are cutting back, and what all this means for HR benefits and total rewards strategy. It also connects the issue to HR career development, including the Refonte Learning Human Resource Management Program, because managing compensation and benefits is a core competency for HR professionals.

The Refonte Learning Human Resource Management Program provides three months of training at 8 to 10 hours per week, covering topics from recruitment to performance and benefits. Its listed competencies explicitly include Compensation & Benefits Administration, making it directly relevant to challenges such as runaway health-plan costs.

The Line Item Nobody Budgeted For

When a benefit category suddenly swallows millions in pharmacy spend, HR leaders notice. Many companies expected only routine cost trends, but GLP-1 medications have upended those assumptions. For example:

·        By mid-2026, some large employers were finding that GLP-1 drugs alone accounted for a double-digit percentage of their entire healthcare spend. Bank of America CEO Brian Moynihan reportedly put the category at roughly 13% of the bank’s more than $2 billion annual health budget.

·        What began as a coverage issue for diabetes patients has become a broad weight-loss coverage question. GLP-1s’ popularity soared, and employers went from seeing them as a small specialty drug line to a major budget line.

·        As one benefits expert described the pattern in WCAX reporting, employers offered GLP-1 coverage, were surprised by the cost, and then began retreating. Mercer survey reporting points to the same pullback.

Even budget requests submitted months before often failed to account for this surge. Many HR teams found themselves renegotiating pharmacy benefits mid-year with PBMs, trying to curb utilization after costs spiked. One HR director described it as “the worst surprise I’ve seen in benefits budgeting”: projections became meaningless once hundreds of employees started using these costly therapies. In short, GLP-1s have become the unexpected line item nobody anticipated in 2026 plans.

How Big Is the GLP-1 Cost Problem, Really

It is tempting to quote eye-popping figures, but careful perspective is needed. Several headline statistics help frame the problem, each with caveats:

·        Bank of America: Quartz’s August 5, 2026 summary of a CNBC interview reported that CEO Brian Moynihan said the bank spends more than $250 million a year on GLP-1 drugs for employees, roughly 13% of a healthcare budget exceeding $2 billion. The figure is company-reported through a media interview rather than an independently filed primary document.

·        Employer coverage rate: MedCity News reported on May 11, 2026 that about 67% of 105 surveyed self-funded employers covered GLP-1s for weight management, while only 72% of those employers expected to continue in 2027. This is a secondary report of a Business Group on Health survey, so methodology and sample composition matter.

·        Overall health-plan trend: Mercer projected a 6.7% increase in average employer health-benefit costs for 2026, pushing the average above $18,500 per employee. GLP-1 spending was one contributor within a wider rise in medical and prescription costs.

·        Cost shifting and coverage cuts: HR Dive’s June 16, 2026 report on Mercer data said nearly half of large employers planned to shift more healthcare costs to employees. It also reported that about 6% had dropped GLP-1 weight-loss coverage in 2026, while another 5% were considering or planning a similar move.

Taken together, these reports show that GLP-1s are a material cost driver in 2026. The exact figures come from media reports, employer statements, or consulting surveys rather than a single standardized dataset, but the direction is consistent: many employers are facing serious cost pressure and are reconsidering how much of it the plan can absorb.

Reading Coverage-Rate Statistics Skeptically

The 67% coverage rate and similar statistics are useful signposts, but not universal facts. The Business Group on Health survey reported by MedCity News covered 105 self-funded employers and focused specifically on weight-management coverage. Actual policies vary by industry, plan sponsor, eligibility rules, and the meaning of “coverage,” which may include strict prior authorization or limited provider networks.

The same caution applies to the reported $250 million Bank of America figure. It is best understood as a CEO-reported estimate conveyed through CNBC and summarized by Quartz, not as an independently audited pharmacy-cost disclosure. Attribution lets readers judge the figure in the proper context.

The Employers Still Absorbing the Cost

Not all companies are pulling back. A visible camp of employers is continuing generous GLP-1 coverage, often viewing it as a long-term investment in employee health. Key examples include:

·        Bank of America (financial services): CEO Brian Moynihan reportedly said the bank spends more than $250 million a year on GLP-1 drugs, roughly 13% of its more than $2 billion healthcare budget. He framed the expense as an investment in workforce wellness and said the bank was pressing drugmakers and pharmacy benefit managers for lower prices.

·        Former adopters show how quickly the calculus can change: Business Insider’s reporting on employer pullbacks noted that Allina Health had covered GLP-1 weight-loss drugs before ending that benefit in 2025. Employers with strong health-benefit commitments may hold the line for a time, then change direction when renewal pressure becomes unsustainable.

·        Broader employer data: The International Foundation of Employee Benefit Plans reported that 36% of surveyed employers covered GLP-1s for both diabetes and weight loss in 2026. That indicates a meaningful group still includes the drugs while experimenting with cost sharing, eligibility controls, and other plan-design changes.

In summary, the “absorb cost” camp tends to be large, well-capitalized organizations that can withstand short-term claims spikes. They usually emphasize potential productivity gains or long-term savings. For example, Bank of America is using its size to negotiate drug rebates and still subsidizing GLP-1s heavily. Other firms may combine coverage with programs like nutritional counseling and coaching to maximize value.

Common features of these employers include: a commitment to employee health culture, willingness to invest in high-cost therapies, and often the financial scale to make bulk drug purchasing deals. Many of these companies also have robust wellness initiatives and may be progressive on other benefits. In corporate communications, they present GLP-1 coverage as part of a holistic health strategy, not a stand-alone perk.

The Employers Pulling Back

At the other extreme, a growing number of employers are explicitly scaling back or reconfiguring GLP-1 coverage. Recent examples documented in news and trade press include:

·        Cigna (health insurer): Reuters reported on June 3, 2026 that Cigna would stop covering Wegovy, Zepbound, and other GLP-1 weight-loss drugs for its own employees effective July 1. The change did not affect GLP-1 treatment for type 2 diabetes or plans Cigna administers for other employers. Employees could still buy the drugs through cash-pay channels, but those purchases would not count toward plan deductibles.

·        Starbucks (retail and food service): Business Insider reported in August 2026 that Starbucks would stop covering GLP-1 medications for weight loss beginning in October as employer costs climbed. The move stands out because Starbucks has long emphasized broad employee benefits.

·        Allina Health (healthcare system): Earlier, in 2025, Minneapolis-based Allina told employees it would end GLP-1 weight-loss coverage because continuing it “would have significantly increased medical premiums” (per a company statement). This reflects a broader caution: even healthcare providers themselves are concerned about premiums.

·        Kane County, Illinois (local government): The Kane County Board’s July 14, 2026 meeting record documents approval of a plan change involving GLP-1 weight-loss coverage. The debate centered on a projected multimillion-dollar insurance increase, annualized GLP-1 spending, and the strain on the county’s reserve fund.

·        UVM Health (Vermont healthcare network): WCAX reported in July 2026 that UVM Health would stop covering GLP-1 drugs for weight loss effective September 1, while preserving diabetes coverage. The network expected to save nearly $19 million annually and cited a budget deficit exceeding $300 million.

·        Public Sector Plans: Apart from Kane County, other state or municipal plans (e.g. some Medicaid programs, union plans) have begun to restrict GLP-1 coverage for weight loss. These moves signal that even smaller public employers are feeling the pressure.

Some common themes in these pullbacks:

·        Most keep covering GLP-1 for diabetes indications but exclude weight-loss prescriptions.

·        Employers cite extraordinary budget impact (often breaking down the costs per claim to emphasize the unsustainability).

·        Many combine the coverage cut with a switch to other programs (e.g. expanded diet/exercise programs).

·        A few have offered to allow employees to pay out-of-pocket (via manufacturer sites or cash options) with no plan reimbursement.

What “Restructuring Coverage” Actually Looks Like

In practice, these cuts take several forms:

·        Benefit design changes: Removing GLP-1s from formulary for weight-loss by default, or requiring prior authorization with strict criteria (e.g. documented BMI, previous weight management program participation).

·        Employee contributions: Some employers shift GLP-1s from a low co-pay tier to the highest tier, dramatically raising employee cost-share.

·        Wellness program linkages: A few require enrollment in a weight-management coaching program as a condition for GLP-1 coverage, to ensure combined lifestyle support.

·        Case management: Some plans channel GLP-1 coverage through dedicated case managers or high-touch specialty pharmacy programs to monitor usage and outcomes.

Overall, pulling back doesn’t always mean a total ban; often it means tightening the rules or moving more costs onto employees. But the examples above show a clear trend: the “hawkish” camp view the GLP-1 budget as unsustainable without change.

Why This Isn’t Just a Big-Company Problem

You might think only huge budgets get broken by these drugs, but smaller employers are affected too. Even small to mid-size firms and public entities have reported significant GLP-1 costs relative to their scale:

·        The Kane County case involved a public employer with roughly 1,080 covered employees, where GLP-1 costs were substantial relative to the size of the plan and its reserve fund.

·        A Maine municipality recently debated cutting GLP-1 coverage after just a few dozen enrollees drove up costs.

·        Even mid-sized self-funded companies see noticeable premium impact. One CFO told a trade publication that a single GLP-1 prescription could add more than $1,000 to overall claims each year for that person, multiplying quickly when tens of employees enroll.

Local reporting has made the small-employer impact visible. WCAX’s coverage of UVM Health and the Kane County Board record show that this is not limited to Fortune 100 companies. Chambers of commerce and community benefit councils are also beginning to factor GLP-1 costs into regional healthcare-cost discussions.

What this shows is that GLP-1 cost pressure compounds existing healthcare affordability challenges for any employer with a self-funded plan, union-negotiated premiums, or a tight budget. The same drivers that make small employers increase premiums (general healthcare inflation, prescription drug trends) now include these high-cost weight-loss meds. So even if you manage a 1,000-person company or a public school district, GLP-1s can feel painfully immediate in your claims data.

What SHRM Is Telling Its Own Members

The HR profession’s leading association is paying attention. On June 29, 2026, SHRM published “Facing High GLP-1 Costs, Employers Shake Up Pharmacy Strategies”. That publication signals that the issue is mainstream in HR practice, not a niche pharmacy story.

In that SHRM piece, the author reports on interviews with benefits consultants, citing figures very similar to what we’ve discussed: Mercer data, employer anecdotes (Starbucks, etc.), and survey stats. The key messages from SHRM’s article include:

·        Coverage redesign: SHRM reported that employers are considering alternate drug-coverage structures, utilization controls, and wellness support to manage GLP-1 costs.

·        Broader pressure: SHRM described employers as being under intense pressure as elevated health costs continue, linking the GLP-1 debate to overall healthcare inflation.

·        Lower cash prices do not remove the demand problem: Reuters reported that lower-dose oral options were available from $149 per month. It remains uncertain whether lower entry prices will offset growing utilization.

·        Pharmacy strategy is changing: GLP-1 spending is reshaping how employers structure PBM contracts, formularies, specialty-drug programs, and wellness support.

For HR pros, this tells us the industry is actively discussing GLP-1 in strategy forums and publications. It’s not just CFOs panicking, benefits leaders and consultants are rethinking pharmacy benefit manager (PBM) contracts, formulary committees, and wellness programs.

SHRM’s endorsement of the topic means readers of that association are seeing this story. A practical takeaway for our context: if your company is wondering whether GLP-1 issues are a fluke, know that SHRM is confirming it’s a credible trend. It also suggests HR professionals should anticipate peer questions at conferences and be ready to contribute to their own organization’s strategy discussions, not just watch from the sidelines.

The Broader Healthcare Cost Trend Behind the Headlines

GLP-1 shocks aren’t happening in isolation. U.S. health benefit costs have been rising for years, and 2026 looks to be another hot year. Citing back-to-back data points:

·        Average cost rise: Mercer projected a 6.7% increase in average employer health-benefit costs in 2026, following a 6.0% increase in 2025 and pushing the average above $18,500 per employee.

·        Employer cost shift: Mercer and HR Dive reported that nearly half of large employers planned to shift more healthcare costs to workers through premiums, deductibles, or copayments.

·        Next year’s forecast: Aon projected a 9.5% increase in U.S. employer healthcare costs for 2027, with average costs expected to exceed $19,000 per employee.

·        Other drivers: Insulin prices, specialty drug inflation, hospital costs, and general medical trend all contribute. Several reports specifically call out rising prescription costs as a major driver, with GLP-1s accelerating that.

What Mercer and Aon’s Numbers Actually Measure

Let’s clarify the Mercer and Aon figures, since they come from large consulting surveys:

·        Mercer’s 6.7% figure: The Mercer projection estimates the total employer health-benefit trend, combining medical and prescription costs across participating plans. It is a market benchmark, not a guarantee for any individual employer.

·        Mercer’s cost-shifting figure: The 2026 employer survey reported by HR Dive reflects stated plans among large employers. It measures employer intentions, not finalized employee contributions across the whole market.

·        Aon’s 9.5% figure: Aon’s 2027 forecast is an actuarial projection based on employer plan data and expected trend. It should be cited as Aon’s estimate rather than a realized cost increase.

These benchmarks are most useful when treated as planning ranges. Mercer’s 6.7% estimate and Aon’s 9.5% projection measure different periods and rely on different methodologies, but both point to sustained healthcare inflation.

The bottom line in this section: Even without GLP-1s, employers were facing rising claims. GLP-1 spending is compounding a problem of high trend. So benefits strategists are contending with a “perfect storm”: hard-to-control medical inflation plus a new disruptive cost.

Pharmacy Benefit Manager Strategy 101

An important lever for controlling drug spend is how you work with the PBM or insurer. HR teams are now questioning if standard PBM approaches can handle GLP-1s. Key strategies being explored include:

·        Formulary management: Employers may tighten prior authorization or step-therapy requirements for GLP-1s. For instance, requiring doctors to show a patient tried older therapies first, or that certain clinical criteria are met.

·        Vendor negotiation: Bank of America’s CEO said the bank was pressing drugmakers and PBMs for lower net prices. Other employers are demanding greater rebate transparency or exploring outcome-based contracts that link payment to results.

·        Separate carve-outs: In rare cases, some employers are considering carving GLP-1 coverage out of the standard plan to a separate specialty-drug program. That can isolate the high costs and potentially allow different funding or stop-loss treatments.

·        High-cost pharmacy programs: Greater use of specialty pharmacy management: e.g. requiring GLP-1 refills to go through a mail-order specialty program that provides extra counseling, monitoring, or bulk pricing.

·        Data analysis: PBMs can report utilization data that flags high-spend drugs. Employers are requesting more granular reports specifically on GLP-1 usage to track trends. Early identification of high utilizers can prompt targeted interventions.

For HR and benefits pros, working with the PBM means asking tough questions: “How is our PBM proposing to manage GLP-1 utilization and costs? Can we segment it differently? Are rebate negotiations sufficient given the trend?” Given the SHRM and industry reports, we’d expect benefits committees to include GLP-1 strategies in their annual planning.

Remember: PBMs traditionally manage diabetes drugs closely, but GLP-1 for obesity is relatively new. Some PBM networks have or are developing "weight-management programs" that can be paired with coverage (e.g. requiring enrollee engagement in nutrition coaching). These tend to target long-term outcomes. For example, Novo Nordisk and Lilly have patient-support programs for Wegovy and Zepbound users, employers may require participation.

In short, pharmacy benefit strategy is shifting from a “set it and forget it” model to a “glp1 watch” model. HR teams should check if their third-party administrators have special allowances or guidance for these drugs. It’s now a key item in pharmacy strategy 101 for 2026.

Designing a GLP-1 Policy That Doesn’t Blow Up Next Year

If an employer decides to continue GLP-1 coverage (even in a limited way), careful plan design is crucial. Some suggestions and common tactics include:

·        Define clinical criteria clearly: Require specific diagnoses (e.g. BMI thresholds, documented obesity with co-morbidities) before GLP-1s are covered. Use evidence-based guidelines (such as CDC or AACE obesity management criteria) to set these rules. If you include weight-loss, define exactly what qualifies (e.g. BMI ≥30 or BMI ≥27 plus metabolic syndrome).

·        Use tiered cost-sharing: Place GLP-1 drugs on a high-cost tier in the formulary, maybe with a 20 to 30% coinsurance. This shares cost and may limit enrollment to those who most value it. Some employers are piloting a flat co-pay for GLP-1s to control maximum employer outlay.

·        Limit quantity or duration: Plan for periodic reassessment. For instance, authorize GLP-1 coverage for 6-month blocks with required reporting on patient progress before renewal. This can ensure the medication is delivering weight loss as intended.

·        Tie coverage to programs: Bundling coverage with mandatory enrollment in a weight-management program. If employees must engage with a health coach or attend diet classes to qualify for GLP-1 coverage, that can improve outcomes and justify the spend.

·        Budget forecasting: Build any GLP-1 coverage into next year’s budget from the start. Use current utilization trends to estimate total claims, and set aside contingency funds or stop-loss triggers if possible.

A sustainable policy should make the design logic explicit. The following table turns the most common controls into a practical review framework:

By applying these design elements, an employer can say: “Yes, we cover GLP-1s, but under these conditions.” It’s similar to how some plans handle fertility treatments or other high-cost benefits. The checklist above can be framed as best practices in policy design.

Frequently missed details:

·        Don’t assume outcomes: Many employers expect GLP-1 use to reduce long-term costs (e.g. fewer surgeries, hospital stays). But evidence is still emerging. Track actual data (absenteeism, comorbidity claims) to see if expected savings materialize.

·        Coordinate with Wellness Programs: Don’t let GLP-1 be a standalone. Align it with nutritional counseling, exercise benefits, and mental health resources.

·        Plan Communication: Employees expect transparency. Misspelling the policy change (e.g. saying “Ozempic” generically) can confuse. Use clear FAQs and communications for any new rules (see next section).

·        Legal Compliance: GLP-1 drugs for obesity may intersect with ADA or medical leave issues if an employee has obesity classified as a disability. HR should review any policy cuts for compliance.

What This Means for Total Rewards Strategy Overall

Benefits are only one part of an employer’s total rewards package. The GLP-1 cost crunch has ripple effects on the entire strategy:

·        Wages vs Benefits Tradeoff: Some companies may revisit total compensation balances. If premium costs rise due to GLP-1s, they might have less budget for raises or bonuses. Conversely, if they cut the benefit, they could free up some funds for other rewards.

·        Focus on Value, Not Just Cost: Employers on the absorbing side argue GLP-1 coverage is a form of value-added benefit that could improve retention and productivity. Those cutting back may offer alternate perks (e.g. expanded fitness subsidies) in trade.

·        Equity Considerations: If only some employees (by health status) use GLP-1s, cost allocation becomes a fairness issue. HR must consider how to communicate these changes so that employees feel the total rewards package (salary + benefits) is still competitive overall.

·        Board and Executive Buy-In: For organizations with total rewards committees or boards approving budgets, GLP-1 decisions now enter those conversations. CFOs and benefits heads need to present clear ROI analyses.

Where Benefits Fit Alongside Pay and Equity

The GLP-1 question highlights a broader issue: how should employers balance benefit generosity with salary competitiveness? Most employees care about both take-home pay and health coverage. When a new cost driver hits, senior HR leaders may need to shift the mix while keeping the overall package competitive.

Refonte’s Pay Transparency Compliance Checklist covers a distinct compensation topic, but it reinforces the same operational lesson: total rewards decisions require coordination across pay, benefits, fairness, and communication.

In sum, GLP-1 issues may push employers to reevaluate whether more benefits spending (on drugs) is reducing their ability to invest in wages or other incentives. Strategic HR must manage that balance, and communicate to employees how the whole package, salary, bonus, benefits, holds up in the new cost environment.

Common Mistakes HR Teams Make Redesigning Coverage

When benefits teams try to address GLP-1 costs on the fly, they sometimes stumble. Common errors include:

·        Cutting coverage without a plan: Simply removing the benefit at renewal without explaining why or providing alternatives can backfire. Employees will complain, and HR can lose trust.

·        Poor communication: Using technical terms (e.g. “FORMULARY UPDATE: SECTION 9b”) without explanation leads to confusion. Failing to provide FAQs or training benefits reps on the change creates frustration.

·        Ignoring budgeting: Some well-meaning HR teams kept coverage too long, then got hit with a surprise renewal rate. Proactive modeling (as above) is key.

·        Not involving key stakeholders: If pharmacy managers or legal counsel aren’t looped in, you might miss regulatory issues or better negotiation strategies.

·        Cherry-picking data: Only looking at current month costs without trend context can cause panic. Conversely, assuming costs will drop fast because of oral GLP-1 drugs might be wishful thinking. Use multi-year projections.

Cutting Coverage Without a Communication Plan

Most failures occur when HR announces a plan-design change without a communication strategy. Build the message, manager support, employee resources, and feedback channels before the announcement.

·        Inform early: Announce changes well before implementation.

·        Explain “why”: Give a simple cost-driver explanation.

·        Highlight continuity: Emphasize what remains covered (e.g. GLP-1s for diabetes).

·        Offer support: Direct employees to open enrollment counselors or helplines for individual questions.

·        Monitor reaction: Use surveys or town halls to ensure messages were received.

Talking to Employees About a Benefits Change Like This

Changing a benefit, especially one tied to weight and health, is sensitive. Best practices for communication and counseling include:

·        Framing it as a business decision: Emphasize that budget constraints require rebalancing. Avoid language that stigmatizes obesity or makes employees feel judged.

·        Empathy and resources: Acknowledge that employees rely on these treatments. Provide contacts for HR and health coaches who can guide alternatives.

·        Privacy: When discussing covered conditions (like diabetes vs obesity), do so respectfully. Remind staff that the plan still covers GLP-1s for diabetes.

·        Depersonalize: When possible, talk about plan-level decisions rather than individual cases. (“Our data shows trend increases” rather than “We know you personally use these drugs.”)

·        Benefits champions: Line managers should be briefed too, since they may get employee questions. Equip them with a one-sheet FAQ.

Tactful, clear communication can reduce the backlash of a cut and open a broader conversation about wellness support. Some employers pair the change with expanded weight-management coaching or fitness benefits. Presenting the decision as a thoughtful reallocation, rather than a blunt removal, can help preserve goodwill.

HR should also prepare for compliance questions. A benefits change may affect nondiscrimination, disability-accommodation, leave, and plan-notice processes, so the implementation team should review the policy and apply it consistently.

HR Manager Skills and Salaries in 2026

HR managers need strong analytical and financial skills to handle challenges like this. The ability to work with benefits consultants, interpret claims data, and explain plan tradeoffs is central to compensation and benefits administration, a competency explicitly listed by Refonte Learning’s program.

Refonte Learning’s program page markets a “$105.0K+” starting salary and “170K+” annual openings for Human Resource Management careers. Those are the provider’s own marketing figures, not independently verified labor statistics. For comparison, ZipRecruiter listed the average U.S. HR Manager salary at $86,139 as of August 18, 2026, with most salaries ranging from $69,000 to $100,000 and the 90th percentile at $118,500. The external benchmark was checked on August 25, 2026.

For a related but distinct career-path discussion, Refonte’s HR Generalist vs. HR Business Partner guide explains how broad operational HR experience can develop into a more strategic partnership role. Benefits expertise is valuable across both paths, especially when plan design affects budgets, employee relations, and business priorities.

·        Benefits analytics and financial modeling: Interpret claims data, test utilization scenarios, and forecast renewal impact.

·        Vendor and PBM negotiation: Question rebates, formularies, utilization controls, and contract guarantees.

·        HR technology and data fluency: Use HRIS and benefits systems to identify trends and monitor plan performance.

·        Strategic total rewards planning: Balance health benefits with pay, bonuses, equity, and retention priorities.

·        Change communication: Translate a complex plan decision into clear, empathetic guidance for employees and managers.

The program lists career outcomes including HR Manager, HR Business Partner, Employee Relations Manager, Talent Acquisition Specialist, and Training & Development Manager. The HR Generalist vs. HR Business Partner guide provides additional context on how those pathways differ.

HR professionals managing benefits need to be comfortable with numbers and strategy as well as the interpersonal work of communicating difficult changes. The Refonte Learning Human Resource Management Program is directly relevant because it explicitly includes Compensation & Benefits Administration among its listed competencies.

Building This Skill Set: The Refonte Learning Human Resource Management Program

Designing benefits, balancing total rewards, interpreting surveys, and communicating changes all connect to Compensation & Benefits Administration. That competency is listed on the Refonte Learning Human Resource Management Program page. The curriculum does not specifically name GLP-1 drugs or PBM strategy, but the listed competency is a direct and legitimate match for the work described in this article.

·        Format: Three months, with an expected commitment of 8 to 10 hours per week.

·        Curriculum: Introduction to Human Resource Management; Talent Acquisition and Recruitment Strategies; Performance Management and Employee Engagement.

·        Relevant competencies: Compensation & Benefits Administration, HR Analytics & Metrics, Labor Laws & Compliance, Conflict Resolution & Employee Relations, Organizational Development, and HR Technology & HRIS Tools, among ten listed competencies.

·        Mentor: Professor Kevin Harris, Department of Digital Marketing, with more than 15 years of experience in talent management and organizational development.

·        Career outcomes: HR Manager, Talent Acquisition Specialist, Employee Relations Manager, HR Business Partner, and Training & Development Manager.

For learners who want practical HR skills, the program connects broad HR foundations with the analytical, communication, and stakeholder-management work required in mid-career roles. That foundation can make an HR professional more confident when reviewing a benefits budget, presenting options to finance, or sitting across from a broker or vendor to renegotiate coverage.

Explore the Refonte Learning Human Resource Management Program to review the full curriculum, competencies, mentor profile, format, and career outcomes.

GLP-1 drug coverage has become a real-world test of compensation and benefits administration. HR teams that can read the data, negotiate pharmacy terms, model scenarios, and communicate change are better positioned to protect both plan sustainability and employee trust. Those are precisely the kinds of transferable HR capabilities highlighted by the Refonte Learning Human Resource Management Program.